Dr. William on Brentuximab Vedotin/Lenalidomide in Cutaneous/Peripheral T-Cell Lymphomas
1 Views
administrator
08/09/23
Basem William, MD, MRCP, FACP associate professor of internal medicine, The Ohio State University, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.
Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive/
-
Category
Show more
Facebook Comments
No comments found